Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab DRCR.NET protocol I 5-year report

Susan B Bressler, Isoken Odia, Adam R. Glassman, Ronald P. Danis, Sandeep Grover, G. Robert Hampton, Lee M. Jampol, Maureen G. Maguire, Michele Melia

Research output: Contribution to journalArticle

Abstract

Purpose: To explore 5-year changes from baseline in diabetic retinopathy severity among eyes treated with ranibizumab for diabetic macular edema. Methods: Diabetic retinopathy severity was assessed from study visits and annual fundus photographs among participants in Protocol I (DRCR.net). The proportion of eyes that improved at annual examinations and the cumulative probability of worsening through 5 years were estimated. Results: Among 235 participants with nonproliferative diabetic retinopathy at baseline, there were 29%, 28%, and 32% of eyes with retinopathy improvement at 1, 3, and 5 years, respectively. Among 111 participants with proliferative diabetic retinopathy, corresponding improvement percentages were 38%, 35%, and 23%. The 5-year cumulative probability of worsening was 18% (95% CI: 14%-25%) among nonproliferative diabetic retinopathy eyes and 31% (95% CI: 23%-42%) among proliferative diabetic retinopathy eyes (P = 0.01). In Years 1, 3, and 5, the mean (SD) number of ranibizumab injections was 8.1 (2.5), 2.2 (2.6), and 1.8 (2.6) for nonproliferative diabetic retinopathy eyes, and 9.0 (2.8), 2.3 (2.9), and 1.7 (2.6) for proliferative diabetic retinopathy eyes, respectively. Proportions with improvement or rates of worsening did not change with time. Conclusion: Individuals receiving ranibizumab therapy for diabetic macular edema may have favorable changes in DR severity throughout a 5-year period concomitant with sequential reduction in anti-vascular endothelial growth factor therapy.

Original languageEnglish (US)
Pages (from-to)1896-1904
Number of pages9
JournalRetina
Volume38
Issue number10
DOIs
StatePublished - Jan 1 2018

Fingerprint

Macular Edema
Diabetic Retinopathy
Ranibizumab
Vascular Endothelial Growth Factor A
Injections
Therapeutics

Keywords

  • Diabetic macular edema
  • Ranibizumab
  • Retinopathy

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab DRCR.NET protocol I 5-year report. / Bressler, Susan B; Odia, Isoken; Glassman, Adam R.; Danis, Ronald P.; Grover, Sandeep; Robert Hampton, G.; Jampol, Lee M.; Maguire, Maureen G.; Melia, Michele.

In: Retina, Vol. 38, No. 10, 01.01.2018, p. 1896-1904.

Research output: Contribution to journalArticle

Bressler, SB, Odia, I, Glassman, AR, Danis, RP, Grover, S, Robert Hampton, G, Jampol, LM, Maguire, MG & Melia, M 2018, 'Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab DRCR.NET protocol I 5-year report', Retina, vol. 38, no. 10, pp. 1896-1904. https://doi.org/10.1097/IAE.0000000000002302
Bressler, Susan B ; Odia, Isoken ; Glassman, Adam R. ; Danis, Ronald P. ; Grover, Sandeep ; Robert Hampton, G. ; Jampol, Lee M. ; Maguire, Maureen G. ; Melia, Michele. / Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab DRCR.NET protocol I 5-year report. In: Retina. 2018 ; Vol. 38, No. 10. pp. 1896-1904.
@article{81f7731a31a243bcbcddeff3a517cd30,
title = "Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab DRCR.NET protocol I 5-year report",
abstract = "Purpose: To explore 5-year changes from baseline in diabetic retinopathy severity among eyes treated with ranibizumab for diabetic macular edema. Methods: Diabetic retinopathy severity was assessed from study visits and annual fundus photographs among participants in Protocol I (DRCR.net). The proportion of eyes that improved at annual examinations and the cumulative probability of worsening through 5 years were estimated. Results: Among 235 participants with nonproliferative diabetic retinopathy at baseline, there were 29{\%}, 28{\%}, and 32{\%} of eyes with retinopathy improvement at 1, 3, and 5 years, respectively. Among 111 participants with proliferative diabetic retinopathy, corresponding improvement percentages were 38{\%}, 35{\%}, and 23{\%}. The 5-year cumulative probability of worsening was 18{\%} (95{\%} CI: 14{\%}-25{\%}) among nonproliferative diabetic retinopathy eyes and 31{\%} (95{\%} CI: 23{\%}-42{\%}) among proliferative diabetic retinopathy eyes (P = 0.01). In Years 1, 3, and 5, the mean (SD) number of ranibizumab injections was 8.1 (2.5), 2.2 (2.6), and 1.8 (2.6) for nonproliferative diabetic retinopathy eyes, and 9.0 (2.8), 2.3 (2.9), and 1.7 (2.6) for proliferative diabetic retinopathy eyes, respectively. Proportions with improvement or rates of worsening did not change with time. Conclusion: Individuals receiving ranibizumab therapy for diabetic macular edema may have favorable changes in DR severity throughout a 5-year period concomitant with sequential reduction in anti-vascular endothelial growth factor therapy.",
keywords = "Diabetic macular edema, Ranibizumab, Retinopathy",
author = "Bressler, {Susan B} and Isoken Odia and Glassman, {Adam R.} and Danis, {Ronald P.} and Sandeep Grover and {Robert Hampton}, G. and Jampol, {Lee M.} and Maguire, {Maureen G.} and Michele Melia",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/IAE.0000000000002302",
language = "English (US)",
volume = "38",
pages = "1896--1904",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab DRCR.NET protocol I 5-year report

AU - Bressler, Susan B

AU - Odia, Isoken

AU - Glassman, Adam R.

AU - Danis, Ronald P.

AU - Grover, Sandeep

AU - Robert Hampton, G.

AU - Jampol, Lee M.

AU - Maguire, Maureen G.

AU - Melia, Michele

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: To explore 5-year changes from baseline in diabetic retinopathy severity among eyes treated with ranibizumab for diabetic macular edema. Methods: Diabetic retinopathy severity was assessed from study visits and annual fundus photographs among participants in Protocol I (DRCR.net). The proportion of eyes that improved at annual examinations and the cumulative probability of worsening through 5 years were estimated. Results: Among 235 participants with nonproliferative diabetic retinopathy at baseline, there were 29%, 28%, and 32% of eyes with retinopathy improvement at 1, 3, and 5 years, respectively. Among 111 participants with proliferative diabetic retinopathy, corresponding improvement percentages were 38%, 35%, and 23%. The 5-year cumulative probability of worsening was 18% (95% CI: 14%-25%) among nonproliferative diabetic retinopathy eyes and 31% (95% CI: 23%-42%) among proliferative diabetic retinopathy eyes (P = 0.01). In Years 1, 3, and 5, the mean (SD) number of ranibizumab injections was 8.1 (2.5), 2.2 (2.6), and 1.8 (2.6) for nonproliferative diabetic retinopathy eyes, and 9.0 (2.8), 2.3 (2.9), and 1.7 (2.6) for proliferative diabetic retinopathy eyes, respectively. Proportions with improvement or rates of worsening did not change with time. Conclusion: Individuals receiving ranibizumab therapy for diabetic macular edema may have favorable changes in DR severity throughout a 5-year period concomitant with sequential reduction in anti-vascular endothelial growth factor therapy.

AB - Purpose: To explore 5-year changes from baseline in diabetic retinopathy severity among eyes treated with ranibizumab for diabetic macular edema. Methods: Diabetic retinopathy severity was assessed from study visits and annual fundus photographs among participants in Protocol I (DRCR.net). The proportion of eyes that improved at annual examinations and the cumulative probability of worsening through 5 years were estimated. Results: Among 235 participants with nonproliferative diabetic retinopathy at baseline, there were 29%, 28%, and 32% of eyes with retinopathy improvement at 1, 3, and 5 years, respectively. Among 111 participants with proliferative diabetic retinopathy, corresponding improvement percentages were 38%, 35%, and 23%. The 5-year cumulative probability of worsening was 18% (95% CI: 14%-25%) among nonproliferative diabetic retinopathy eyes and 31% (95% CI: 23%-42%) among proliferative diabetic retinopathy eyes (P = 0.01). In Years 1, 3, and 5, the mean (SD) number of ranibizumab injections was 8.1 (2.5), 2.2 (2.6), and 1.8 (2.6) for nonproliferative diabetic retinopathy eyes, and 9.0 (2.8), 2.3 (2.9), and 1.7 (2.6) for proliferative diabetic retinopathy eyes, respectively. Proportions with improvement or rates of worsening did not change with time. Conclusion: Individuals receiving ranibizumab therapy for diabetic macular edema may have favorable changes in DR severity throughout a 5-year period concomitant with sequential reduction in anti-vascular endothelial growth factor therapy.

KW - Diabetic macular edema

KW - Ranibizumab

KW - Retinopathy

UR - http://www.scopus.com/inward/record.url?scp=85064074830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064074830&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000002302

DO - 10.1097/IAE.0000000000002302

M3 - Article

C2 - 30234859

AN - SCOPUS:85064074830

VL - 38

SP - 1896

EP - 1904

JO - Retina

JF - Retina

SN - 0275-004X

IS - 10

ER -